Literature DB >> 7926312

Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria.

P Fioretto1, M W Steffes, M Mauer.   

Abstract

Although microalbuminuria is known to foretell the later development of overt proteinuria in patients with insulin-dependent diabetes mellitus (IDDM), different investigators have reported different levels of albuminuria as being predictive. However, whether different levels of albuminuria reflect differences in glomerular structure is not well known. In this study, we divided a cohort of 66 nonproteinuric long-standing (duration 20 +/- 7 years) IDDM patients, who had both renal functional and structural studies performed, into four groups according to their urinary albumin excretion rate (AER). The several different levels of microalbuminuria previously reported to be predictive served to demarcate these groups: group I, AER < or = 22 mg/24 h (upper limit for normal in our laboratory) (33 patients); group II, AER 23-45 mg/24 h (11 patients); group III, AER 46-100 mg/24 h (13 patients); and group IV, AER 101-220 mg/24 h (9 patients). Creatinine clearance was similar in groups I, II, and III but was lower in group IV. Systemic hypertension was present in five patients in group I, one in group II, seven in group III, and five in group IV. Mean values for glomerular basement membrane (GBM) width and volume fraction of the mesangium [Vv(mes/glom)] were greater in all groups than in a group of 52 age-matched normal kidney donors (P < 0.0001). Also, filtration surface density [Sv(PGBM)], inversely related to Vv(mes/glom) (r = 0.61, P < 0.0001), was reduced in all diabetic groups compared with the normal group (P < 0.0001). Structural measures were identical in group I and II.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 7926312     DOI: 10.2337/diab.43.11.1358

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  63 in total

Review 1.  The meaning of microalbuminuria in type 1 diabetes: the need for a new paradigm.

Authors:  S G Adler; C C Nast
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 2.  Growth factors and diabetic nephropathy: kidney structure and therapeutic interventions.

Authors:  R W Bilous; P Fioretto; P Czernichow; K Drummond
Journal:  Diabetologia       Date:  1997-10       Impact factor: 10.122

3.  Prevention of decline in renal function in the diabetic db/db mouse.

Authors:  M P Cohen; R S Clements; J A Cohen; C W Shearman
Journal:  Diabetologia       Date:  1996-03       Impact factor: 10.122

4.  Changes in Albuminuria But Not GFR are Associated with Early Changes in Kidney Structure in Type 2 Diabetes.

Authors:  Helen C Looker; Michael Mauer; Pierre-Jean Saulnier; Jennifer L Harder; Viji Nair; Carine M Boustany-Kari; Paolo Guarnieri; Jon Hill; Cordell A Esplin; Matthias Kretzler; Robert G Nelson; Behzad Najafian
Journal:  J Am Soc Nephrol       Date:  2019-06       Impact factor: 10.121

5.  The relationship of retinal vessel diameter to changes in diabetic nephropathy structural variables in patients with type 1 diabetes.

Authors:  R Klein; M D Knudtson; B E K Klein; B Zinman; R Gardiner; S Suissa; A R Sinaiko; S M Donnelly; P Goodyer; T Strand; M Mauer
Journal:  Diabetologia       Date:  2010-05-01       Impact factor: 10.122

Review 6.  Urinary biomarkers for early diabetic nephropathy: beyond albuminuria.

Authors:  So-Young Lee; Mary E Choi
Journal:  Pediatr Nephrol       Date:  2014-07-25       Impact factor: 3.714

Review 7.  Risk predictors in patients with diabetic nephropathy.

Authors:  P Fioretto; M L Caramori; M Dalla Vestra; M Mauer
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 8.  The relationship between glucose control and the development and progression of diabetic nephropathy.

Authors:  Carrie A Phillips; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2002-12       Impact factor: 4.810

Review 9.  The natural progression of kidney injury in young type 1 diabetic patients.

Authors:  Julia M Steinke
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

10.  The effects of candesartan on diabetes glomerulopathy: a double-blind, placebo-controlled trial.

Authors:  Nina E S S Perrin; Georg A Jaremko; Ulla B Berg
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.